Clinical trials: Paclitaxel
Recurrent Adenocarcinoma of the Pancreas, Metastatic Adenocarcinoma of the Pancreas
Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas
Phase II Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas.
- Trial name
- NCT02739633
- Testing
- Genexol-PM, Gemcitabine
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Carcinoma, Non-Small-Cell Lung
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the…
- Trial name
- NCT00147537
- Testing
- CP-751,871, paclitaxel, carboplatin
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Pfizer
Squamous Cell Carcinoma
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with SCC who have progressed on or after previous platinum-based chemotherapy and anti-PD-1/PD-L1 therapy.
- Trial name
- NCT03387111
- Testing
- Aldoxorubicin HCl, ETBX-011, ETBX-021
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- ImmunityBio, Inc.
Coronary Artery Disease
TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions
TAXUS ATLAS is a global, multi-center, single-arm, non-inferiority trial comparing results from patients treated with the TAXUS Liberté stent to an historical TAXUS Express control.
- Trial name
- NCT00371709
- Testing
- TAXUS Liberté-SR, TAXUS™ Express
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 871 people
- Sponsor
- Boston Scientific Corporation
Triple Negative Breast Cancer
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and…
- Trial name
- IMpassion030 (NCT03498716)
- Testing
- Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin
- Where
- 364 sites in United States, Argentina and 29 more
- Volunteers
- 2,199 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer Recurrent
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly.
- Trial name
- NCT06843447
- Testing
- Raludotatug Deruxtecan, Carboplatin, Paclitaxel
- Where
- 40 sites in United States, Australia and 7 more
- Volunteers
- 605 people
- Sponsor
- Merck Sharp & Dohme LLC
Peripheral Artery Disease
Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis
A prospective randomized trial designed to compare the efficacy and safety of Sirolimus coated balloon (SCB) versus paclitaxel coated balloon (DCB) in the treatment of femoropopliteal artery stenosis
- Trial name
- NCT04982367
- Testing
- Sirolimus-eluting balloon catheter, Paclitaxel-eluting balloon catheter
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Acotec Scientific Co., Ltd
Non Small Cell Lung Carcinoma
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
The primary objective of the trial is to determine the Maximum tolerated dose, if any, of the combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up to 45 mg/m2 paclitaxel.
- Trial name
- NCT00252798
- Testing
- Gefitinib, Carboplatin, Paclitaxel
- Where
- 2 sites in Australia
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Ovarian Neoplasms
CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
The objective of this study is to compare the efficacy and safety of CAELYX versus Paclitaxel HCl in patients with epithelial ovarian carcinoma following failure of first-line, platinum-based chemotherapy.
- Trial name
- NCT00653952
- Testing
- CAELYX, Paclitaxel HCl
- Volunteers
- 220 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ovarian Cancer
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
This study will evaluate the efficacy and safety of pertuzumab in combination with carboplatin-based standard chemotherapy in patients with platinum-sensitive recurrent ovarian cancer.
- Trial name
- NCT02004093
- Testing
- pertuzumab, paclitaxel, gemcitabine
- Where
- 34 sites in Belgium, Canada and 7 more
- Volunteers
- 149 people
- Sponsor
- Hoffmann-La Roche
Cervical Cancer
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Phase II study: a study to explore the safety and preliminary efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab Phase III study: a confirmatory study to evaluate the safety and efficacy of BAT1308…
- Trial name
- NCT06123884
- Testing
- Recombinant humanized anti-PD-1 monoclonal antibody injection, Cisplatin, Bevacizumab Injection
- Where
- China
- Volunteers
- 526 people
- Sponsor
- Bio-Thera Solutions
P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
This study is a Phase 1b/2 multi-center study to assess the safety, tolerability, pharmacokinetics of CTX-009 (ABL001) in combination with Irinotecan or Paclitaxel in patients with advanced or metastatic solid tumors.
- Trial name
- NCT04492033
- Testing
- CTX-009 (ABL001), Paclitaxel, Irinotecan
- Where
- 4 sites in South Korea
- Volunteers
- 41 people
- Sponsor
- Handok Inc.
Advanced/Metastatic Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III…
- Trial name
- NCT00723957
- Testing
- Ixabepilone, 32 mg/m^2, Paclitaxel, 200 mg/m^2, Carboplatin (area under the concentration curve [AUC] 6)
- Where
- 33 sites in United States, Argentina and 8 more
- Volunteers
- 260 people
- Sponsor
- R-Pharm
Carcinoma, Non-Small-Cell Lung
A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
The primary objectives of this trial were to determine the MTD of BIBF 1120 in combination with carboplatin and paclitaxel, pharmacokinetics and objective response of treatment
- Trial name
- NCT02182232
- Testing
- BIBF 1120, Paclitaxel, Carboplatin
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with…
- Trial name
- NCT00113516
- Testing
- carboplatin, paclitaxel, sunitinib
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 84 people
- Sponsor
- Pfizer
Triple Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast…
- Trial name
- NCT05112536
- Testing
- Trilaciclib, Cylophosphamide, Doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- G1 Therapeutics, Inc.
Breast Cancer
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before.
- Trial name
- NCT03734029
- Testing
- Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin
- Where
- 208 sites in United States, Austria and 18 more
- Volunteers
- 557 people
- Sponsor
- Daiichi Sankyo
Non-small-cell Lung Cancer
E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to determined the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 administered continually twice daily in combination with…
- Trial name
- NCT00832819
- Testing
- E7080, Paclitaxel, Carboplatin
- Where
- 3 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Eisai Co., Ltd.
Tumors
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety, tolerability and efficacy of combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with bevacizumab (Avastin), carboplatin and paclitaxel in patients…
- Trial name
- FALCON (NCT00653939)
- Testing
- Fosbretabulin, Carboplatin, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mateon Therapeutics
Neoplasms
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology.
- Trial name
- NCT02723955
- Testing
- feladilimab (GSK3359609), GSK3174998, Pembrolizumab
- Where
- 28 sites in United States, Australia and 7 more
- Volunteers
- 829 people
- Sponsor
- GlaxoSmithKline